NEW YORK (GenomeWeb News) – TriLink BioTechnologies announced today a licensing deal with QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligos.
TINA molecules are intercalators used to stabilize duplex formation, TriLink said, adding their properties improve the sensitivity and specificity of endpoint and real-time PCR. TriLink will makes TINA-modified oligonucleotides available starting next month.
Financial and other terms of the deal were not disclosed.
TriLink, based in San Diego, manufactures custom oligonucleotides, modified nucleoside triphosphates, and CleanAmp PCR products for the diagnostic and original equipment manufacturer markets.
Hvidovre, Denmark-based QuantiBact develops nucleic acid tools for research and diagnostic purposes.